These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 22434288)

  • 1. Risk scoring system for prediction of contrast-induced nephropathy in patients with pre-existing renal impairment undergoing percutaneous coronary intervention.
    Chong E; Shen L; Poh KK; Tan HC
    Singapore Med J; 2012 Mar; 53(3):164-9. PubMed ID: 22434288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of anemia on contrast-induced nephropathy (CIN) in patients undergoing percutaneous coronary interventions.
    Li WH; Li DY; Han F; Xu TD; Zhang YB; Zhu H
    Int Urol Nephrol; 2013 Aug; 45(4):1065-70. PubMed ID: 23225080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine.
    Chen SL; Zhang J; Yei F; Zhu Z; Liu Z; Lin S; Chu J; Yan J; Zhang R; Kwan TW
    Int J Cardiol; 2008 Jun; 126(3):407-13. PubMed ID: 17651830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrast-induced nephropathy in urgent coronary interventions.
    Valente S; Lazzeri C; Giglioli C; Margheri M; Comeglio M; Nicolaci L; Chechi T; Gensini GF
    J Cardiovasc Med (Hagerstown); 2006 Oct; 7(10):737-41. PubMed ID: 17001234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ratio of contrast volume to glomerular filtration rate predicts outcomes after percutaneous coronary intervention for ST-segment elevation acute myocardial infarction.
    Mager A; Vaknin Assa H; Lev EI; Bental T; Assali A; Kornowski R
    Catheter Cardiovasc Interv; 2011 Aug; 78(2):198-201. PubMed ID: 20949583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of hydration with or without n-acetylcysteine on contrast induced nephropathy in patients undergoing coronary angiography and percutaneous coronary intervention.
    Awal A; Ahsan SA; Siddique MA; Banerjee S; Hasan MI; Zaman SM; Arzu J; Subedi B
    Mymensingh Med J; 2011 Apr; 20(2):264-9. PubMed ID: 21522098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors and clinical outcomes for contrast-induced nephropathy after percutaneous coronary intervention in patients with normal serum creatinine.
    Chong E; Poh KK; Liang S; Tan HC
    Ann Acad Med Singap; 2010 May; 39(5):374-80. PubMed ID: 20535427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age, glomerular filtration rate, ejection fraction, and the AGEF score predict contrast-induced nephropathy in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
    Andò G; Morabito G; de Gregorio C; Trio O; Saporito F; Oreto G
    Catheter Cardiovasc Interv; 2013 Nov; 82(6):878-85. PubMed ID: 23703775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CHADS2 score predicts risk of contrast-induced nephropathy in stable coronary artery disease patients undergoing percutaneous coronary interventions.
    Chou RH; Huang PH; Hsu CY; Leu HB; Huang SS; Huang CC; Chen JW; Lin SJ
    J Formos Med Assoc; 2016 Jul; 115(7):501-9. PubMed ID: 26830105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contrast induced nephropathy in patients with pre-existing renal impairment undergoing coronary angiogram and percutaneous transluminal coronary angioplasty.
    Subedi B; Siddique MA; Zaman SM; Hasan MI; Arzu J; Awal A; Fatema K
    Mymensingh Med J; 2011 Apr; 20(2):270-4. PubMed ID: 21522099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors of contrast-induced nephropathy in patients undergoing primary coronary angioplasty.
    Ivanes F; Isorni MA; Halimi JM; Fauchier L; Saint Etienne C; Babuty D; Angoulvant D; Brunet-Bernard A
    Arch Cardiovasc Dis; 2014; 107(8-9):424-32. PubMed ID: 25082735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial.
    Chong E; Poh KK; Lu Q; Zhang JJ; Tan N; Hou XM; Ong HY; Azan A; Chen SL; Chen JY; Ali RM; Fang WY; Lau TW; Tan HC
    Int J Cardiol; 2015 Dec; 201():237-42. PubMed ID: 26301645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the definition utilized on the rate of contrast-induced nephropathy in percutaneous coronary intervention.
    Jabara R; Gadesam RR; Pendyala LK; Knopf WD; Chronos N; Chen JP; Viel K; King SB; Manoukian SV
    Am J Cardiol; 2009 Jun; 103(12):1657-62. PubMed ID: 19539072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of contrast-induced nephropathy in diabetic patients undergoing elective cardiac catheterization or PCI: role of volume-to-creatinine clearance ratio and iodine dose-to-creatinine clearance ratio.
    Worasuwannarak S; Pornratanarangsi S
    J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S29-34. PubMed ID: 20364554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumour necrosis factor receptors 1 and 2 predict contrast-induced nephropathy and progressive renal dysfunction: a prospective cohort study.
    An JN; Yoo KD; Hwang JH; Kim HL; Kim SH; Yang SH; Kim JH; Kim DK; Oh YK; Kim YS; Lim CS; Lee JP
    Nephrology (Carlton); 2015 Aug; 20(8):552-9. PubMed ID: 25783484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated homocysteine and the risk of contrast-induced nephropathy: a cohort study.
    Barbieri L; Verdoia M; Schaffer A; Niccoli G; Perrone-Filardi P; Bellomo G; Marino P; Suryapranata H; Luca GD
    Angiology; 2015 Apr; 66(4):333-8. PubMed ID: 24830422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The changing definition of contrast-induced nephropathy and its clinical implications: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
    Slocum NK; Grossman PM; Moscucci M; Smith DE; Aronow HD; Dixon SR; Share D; Gurm HS
    Am Heart J; 2012 May; 163(5):829-34. PubMed ID: 22607861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
    Patti G; Ricottini E; Nusca A; Colonna G; Pasceri V; D'Ambrosio A; Montinaro A; Di Sciascio G
    Am J Cardiol; 2011 Jul; 108(1):1-7. PubMed ID: 21529740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of contrast-induced nephropathy in chronic total occlusion percutaneous coronary intervention.
    Lin YS; Fang HY; Hussein H; Fang CY; Chen YL; Hsueh SK; Cheng CI; Yang CH; Chen CJ; Hang CL; Yip HK; Wu CJ
    EuroIntervention; 2014 Feb; 9(10):1173-80. PubMed ID: 24561734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contrast-Induced Nephropathy in STEMI Patients With and Without Chronic Kidney Disease.
    Jain T; Shah S; Shah J; Jacobsen G; Khandelwal A
    Crit Pathw Cardiol; 2018 Mar; 17(1):25-31. PubMed ID: 29432373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.